Akero Therapeutics (AKRO)

• Market cap: $4.47B
• 1 day: 0.18%
• 5 days: 0.39%
• 1 month: 0.95%
• 3 months: 11.85%
• 6 months: 42.5%
• Year to date: 93.55%
• 1 year: 83.86%
• 5 years: 84.8%
• 10 years: 196.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Employees: 67